DaVita Inc. (NYSE:DVA) Shares Bought by Cubist Systematic Strategies LLC (2024)

Cubist Systematic Strategies LLC raised its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 156.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 136,265 shares of the company's stock after acquiring an additional 83,183 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.15% of DaVita worth $14,275,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC grew its position in shares of DaVita by 17.6% in the third quarter. Janney Montgomery Scott LLC now owns 6,873 shares of the company's stock valued at $650,000 after purchasing an additional 1,031 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of DaVita by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 563,727 shares of the company's stock valued at $53,289,000 after purchasing an additional 14,318 shares in the last quarter. Van ECK Associates Corp grew its position in shares of DaVita by 309.1% in the third quarter. Van ECK Associates Corp now owns 27,216 shares of the company's stock valued at $2,573,000 after purchasing an additional 20,563 shares in the last quarter. Pathstone Family Office LLC purchased a new stake in shares of DaVita in the third quarter valued at approximately $336,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of DaVita in the third quarter valued at approximately $1,172,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DVA shares. Barclays upped their price target on DaVita from $133.00 to $150.00 and gave the company an "equal weight" rating in a research report on Monday, May 6th. StockNews.com lowered DaVita from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Truist Financial increased their price objective on DaVita from $135.00 to $150.00 and gave the stock a "hold" rating in a research report on Wednesday, May 15th. Finally, UBS Group increased their price objective on DaVita from $113.00 to $134.00 and gave the stock a "buy" rating in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $144.67.

Get Our Latest Stock Analysis on DaVita

DaVita Trading Up 2.0 %

DaVita stock traded up $2.84 during mid-day trading on Wednesday, hitting $142.70. The company's stock had a trading volume of 700,978 shares, compared to its average volume of 840,448. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $147.93. The stock's fifty day moving average is $136.96 and its two-hundred day moving average is $123.46. The firm has a market capitalization of $12.51 billion, a PE ratio of 16.25, a price-to-earnings-growth ratio of 1.08 and a beta of 0.96. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The business had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same period last year, the business posted $1.58 earnings per share. The company's quarterly revenue was up 6.9% on a year-over-year basis. On average, analysts anticipate that DaVita Inc. will post 9.62 EPS for the current year.

Insider Transactions at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the firm's stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.00% of the company's stock.

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

• Five stocks we like better than DaVita
• 3 Monster Growth Stocks to Buy Now
• Autodesk's Quarterly Results Could Drive It Back to Recent Highs
• Using the MarketBeat Dividend Tax Calculator
• A Bubble is Brewing in Oracle Stock, and it’s Only Getting Bigger
• High Flyers: 3 Natural Gas Stocks for March 2022
• Danaos Benefits from Increasing Demand in Container Shipping

Should you invest $1,000 in DaVita right now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here